LEGN vs LNTH
Legend Biotech Corporation vs Lantheus Holdings — AI-powered side-by-side comparison
LEGN
Legend Biotech Corporation
57
Buy
VS
LNTH
Lantheus Holdings
67
Buy
| Metric | LEGN | LNTH |
|---|
| AI Score |
57
|
67
|
| Price |
$21.83
|
$100.63
|
| P/E Ratio |
-16.05×
|
23.91×
|
| ROE |
-29.6%
|
21.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
55.0%
|
60.1%
|
| Debt / Equity |
0.40×
|
0.44×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
63.1
|
42.5
|
| Beta |
0.369
|
-0.057
|
| Expected Upside |
—
|
+7.8%
|
AI Committee View
Current Innellis committee reasoning for LEGN versus LNTH.
LNTH leads by 10 points.
LNTH scores 67/100 (Buy) versus LEGN at 57/100 (Buy).
LEGN Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 37.0% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- Price structure (HH_HL) contradicts the downtrend -- mixed signals — Technical
- Bollinger bandwidth of 37.0% signals elevated volatility — Risk
LNTH Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical